0
Research Papers

Biodegradable Nanoparticles Surface Modification Techniques With cIBR Peptide Targeting to LFA-1 Expressing Leukemic Cells

[+] Author and Article Information
Rungsinee Phongpradist

Department of Pharmaceutical Sciences,
Faculty of Pharmacy,
Chiang Mai University,
Chiang Mai 50200, Thailand
e-mail: auan_rx@hotmail.com

Chuda Chittasupho

Department of Pharmaceutical Technology,
Srinakharinwirot University,
Nakornnayok 26120, Thailand

Nutjeera Intasai

Division of Clinical Microscopy,
Department of Medical Technology,
Faculty of Associated Medical Sciences,
Chiang Mai University,
Chiang Mai 50200, Thailand

Teruna J. Siahaan

Professor

Cory J. Berkland

Professor
Department of Pharmaceutical Chemistry,
School of Pharmacy,
The University of Kansas,
Lawrence, KS 66047

Pimlak Charoenkwan

Associate Professor
Department of Pediatrics,
Faculty of Medicine,
Chiang Mai University,
Chiang Mai 50200, Thailand

Songyot Anuchapreeda

Assistant Professor
Division of Clinical Microscopy,
Department of Medical Technology,
Faculty of Associated Medical Sciences,
Chiang Mai University,
Chiang Mai 50200, Thailand

Chadarat Ampasavate

Assistant Professor
Department of Pharmaceutical Sciences,
Faculty of Pharmacy,
Chiang Mai University,
Chiang Mai 50200, Thailand
e-mail: aimchadarat@windowslive.com

1Corresponding author.

Manuscript received July 30, 2012; final manuscript received December 26, 2012; published online March 26, 2013. Assoc. Editor: Henry Hess.

J. Nanotechnol. Eng. Med 3(4), 041005 (Mar 26, 2013) (9 pages) doi:10.1115/1.4023896 History: Received July 30, 2012; Revised December 26, 2012

The lymphocyte function associated antigen-1 (LFA-1) is evaluated for a targeting carrier in leukemia. The cIBR peptide was utilized as the targeting moiety for the drug carrier in direct targeting to LFA-1 expressing cancer cells. This study aims to evaluate the effects of the cIBR peptide conjugation on the specific targeting delivery to the leukemic cell line. Poly (D, L lactide-co-glycolide) (PLGA) nanoparticles were conjugated to the cIBR peptide by three different approaches (coupling, head, and tail) in order to evaluate the nanoparticles' characters, targetability, uptake, drug releasing, and cytotoxicity of each approach. The prepared PLGA nanoparticles were spherical lin shape with a size range of 200–450 nm. The targetability and uptake of three types of cIBR-conjugated nanoparticles (cIBR-NPs) were evidenced and quantified by flow cytometry. The coupling approach presented the highest targetability, uptake, drug releasing, and cytotoxicity followed by the head and tail approaches, respectively. The peptide conjugation method onto the nanoparticles surface was proven to be a key factor for the nanoparticles' physicochemical characteristicss and their efficient delivery.

FIGURES IN THIS ARTICLE
<>
Copyright © 2013 by ASME
Topics: Nanoparticles , PLGA , Drugs
Your Session has timed out. Please sign back in to continue.

References

Cho, K., Wang, X., Nie, S., and Shin, D. M., 2008, “Therapeutic Nanoparticles for Drug Delivery in Cancer,” Clin. Cancer. Res., 14(5), pp. 1310–1316. [CrossRef] [PubMed]
Das, M., Mohanty, C., and Sahoo, S. K., 2009, “Ligand-Based Targeted Therapy for Cancer Tissue,” Expert Opin. Drug Deliv., 6(3), pp. 285–304. [CrossRef] [PubMed]
Danhier, F., Feron, O., and Préat, V., 2010, “To Exploit the Tumor Microenvironment: Passive and Active Tumor Targeting of Nanocarriers for Anti-Cancer Drug Delivery,” J. Controlled Release, 148(2), pp. 135–146. [CrossRef]
Gantert, M., Lewrick, F., Adrian, J. E., Rössler, J., Steenpaß, T., Schubert, R., and Peschka-Süss, R., 2009, “Receptor-Specific Targeting With Liposomes In Vitro Based on Sterol-PEG 1300 Anchors,” Pharm. Res., 26(3), pp. 529–538. [CrossRef] [PubMed]
Liu, P., Wang, H., Wang, Q., Sun, Y., Shen, M., Zhu, M., Wan, Z., and Duan, Y. J., 2012, “cRGD Conjugated mPEG-PLGA-PLL Nanoparticles for SGC-7901 Gastric Cancer Cells—Targeted Delivery of Fluorouracil,” J. Nanosci. Nanotechnol., 12(6), pp. 4467–4471. [CrossRef] [PubMed]
Gu, H., Zheng, R., Zhang, X. X., and Xu, B., 2004, “Facile One-Pot Synthesis of Bifunctional Heterodimers of Nanoparticles: A Conjugate of Quantum Dot and Magnetic Nanoparticles,” J. Am. Chem. Soc., 126(18), pp. 5664–5665. [CrossRef] [PubMed]
Mohanraj, V., and Chen, Y., 2007, “Nanoparticles—A Review,” Trop. J. Pharm. Res., 5(1), pp. 561–573. [CrossRef]
Kuo, J. W., Swann, D. A., and Prestwich, G. D., 1991, “Chemical Modification of Hyaluronic Acid by Carbodiimides,” Bioconjugate. Chem., 2(4), pp. 232–241. [CrossRef]
Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., and Mitchell, J., 1993, “Cytotoxic Studies of Paclitaxel (Taxol) in Human Tumour Cell Lines,” Brit. J. Cancer, 68(6), pp. 1104–1109. [CrossRef]
Kuppens, I., 2006, “Current State of the Art of New Tubulin Inhibitors in the Clinic,” Curr. Clin. Pharm., 1(1), pp. 57–70. [CrossRef]
Phongpradist, R., Chittasupho, C., Okonogi, S., Siahaan, T., Anuchapreeda, S., Ampasavate, C., and Berkland, C., 2010, “LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery,” Curr. Pharm. Des., 16(21), pp. 2321–2330. [CrossRef] [PubMed]
Chittasupho, C., Shannon, L., Siahaan, T. J., Vines, C. M., and Berkland, C., 2011, “Nanoparticles Targeting Dendritic Cell Surface Molecules Effectively Block T Cell Conjugation and Shift Response,” ACS Nano, 5(3), pp. 1693–1702. [CrossRef] [PubMed]
Chittasupho, C., Xie, S., Baoum, A., Yakovleva, T., Siahaan, T., and Berkland, C., 2009, “ICAM-1 Targeting of Doxorubicin-Loaded PLGA Nanoparticles to Lung Epithelial Cells,” Eur. J. Pharm. Sci., 37(2), pp. 141–150. [CrossRef] [PubMed]
Mukerjee, A., and Vishwanatha, J., 2009, “Formulation, Characterization and Evaluation of Curcumin-Loaded PLGA Nanospheres for Cancer Therapy,” Anticancer. Res., 29(10), pp. 38–67.
Chittasupho, C., Manikwar, P., Krise, J., Siahaan, T., and Berkland, C., 2010, “cIBR Effectively Targets Nanoparticles to LFA-1 on Acute Lymphoblastic T Cells,” Mol. Pharmaeutics., 7(1), pp. 146–155 [CrossRef].
Benner, S. A., and Eyler, R., 1996, “Analysis of Combinatorial Libraries Using Electrospray Fourier Transform Ion Cyclotron Resonance Mass Spectrometry,” Rapid. Commun. Mass Spectrom., 10, pp. 1860–1864. [CrossRef] [PubMed]
Lim, H. J., Nam, H. Y., Lee, B. H., Kim, D. J., Ko, J. Y., and Park, J., 2007, “A Novel Technique for Loading of Paclitaxel-PLGA Nanoparticles Onto ePTFE Vascular Grafts,” Biotechnol. Prog., 23(3), pp. 693–697. [CrossRef] [PubMed]
Bojat, V., Balabanyan, V., and Alyautdin, R., 2011, “The Entrapment of Paclitaxel in PLGA Nanoparticles Increases Its Cytotoxicity Against Multiresistant Cell Line,” Brit. J. Med. Med. Res., 1(4), pp. 306–319.
Yokoyama, M., 2005, “Drug Targeting With Nano-Sized Carrier Systems,” J. Artif. Organs., 8(2), pp. 77–84. [CrossRef] [PubMed]
Dinarv, R., Sepehri, N., Manoochehri, S., Rouhani, H., and Atyabi, F., 2011, “Polylactide-co-glycolide Nanoparticles for Controlled Delivery of Anticancer Agents,” Int. J. Nanomedicine, 6, pp. 877–895. [CrossRef] [PubMed]
Peer, D., Karp, J., Hong, S., Farokhzad, O., Margalit, R., and Langer, R., 2007, “Nanocarriers as an Emerging Platform for Cancer Therapy,” Nat. Nanotechnol., 2(12), pp. 751–760. [CrossRef] [PubMed]
Mainardes, R. M., and Evangelista, R. C., 2005, “PLGA Nanoparticles Containing Praziquantel: Effect of Formulation Variables on Size Distribution,” Int. J. Pharm., 290(1), pp. 137–144. [CrossRef] [PubMed]
Kempen, D. H. R., Lu, L., Zhu, X., Kim, C., Jabbari, E., Dhert, W. J. A., Currier, B. L., and Yaszemski, M. J., 2004, “Development of Biodegradable Poly (Propylene Fumarate)/Poly (Lactic-Co-Glycolic Acid) Blend Microspheres. I. Preparation and Characterization,” J. Biomed. Mater. Res., 70(2), pp. 283–292. [CrossRef]
Sahana, B., Santra, K., Basu, S., and Mukherjee, B., 2010, “Development of Biodegradable Polymer Based Tamoxifen Citrate Loaded Nanoparticles and Effect of Some Manufacturing Process Parameters on Them: A Physicochemical and In-Vitro Evaluation,” Int. J. Nanomedicine, 5, pp. 621–630 [CrossRef]. [PubMed]
Makadia, H. K., and Siegel, S. J., 2011, “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,” Polymers, 3(3), pp. 1377–1397. [CrossRef] [PubMed]
Faisant, N., Siepmann, J., and Benoit, J. P., 2002, “PLGA-Based Microparticles: Elucidation of Mechanisms and a New, Simple Mathematical Model Quantifying Drug Release,” Eur. J. Pharm. Sci., 15(4), pp. 355–366. [CrossRef] [PubMed]
Kilic, M. A., Ozlu, E., and Calis, S., 2012, “A Novel Protein-Based Anticancer Drug Encapsulating Nanosphere,” J. Biomed. Nanotechnol., 8(3), pp. 508–514. [CrossRef] [PubMed]
Warren, R. A., Green, F. A., and Enns, C. A., 1997, “Saturation of the Endocytic Pathway for the Transferrin Receptor Does Not Affect the Endocytosis of the Epidermal Growth Factor Receptor,” J. Biol. Chem., 272(4), pp. 2116–2121. [CrossRef] [PubMed]
Phongpradist, R., Chiampanichayakul, S., Tima, S., Siahaan, T. J., Berkland, C. J., Anuchapreeda, S., and Ampasavate, C., 2012, “Potential cIBR-Conjugated PLGA Nanoparticles for Selective Targeting to Leukemic Cells,” Waset. org, 6(6), pp. 252–260.

Figures

Grahic Jump Location
Fig. 1

Scheme of the cIBR-Pluronic-PTX-loaded PLGA-NPs (coupling) preparation

Grahic Jump Location
Fig. 2

Scheme of the (a) head to tail conjugation (head), and (b) tail to head conjugation (tail)

Grahic Jump Location
Fig. 3

cIBR-conjugated PLGA-nanoparticle morphology; (a) cIBR-PEG-NPs (tail), (b) cIBR-PEG-NPs (head), and (c) cIBR-NPs (coupling) by transmission electron microscopy (TEM)

Grahic Jump Location
Fig. 4

The standard curve of paclitaxel for the calculation of the entrapment efficiency

Grahic Jump Location
Fig. 5

The flow cytometry results of the cellular uptake of cIBR-NPs (coupling), cIBR-PEG-NPs (tail), and cIBR-PEG-NPs (head) by Molt-3. Gray-filled histograms represent the fluorescent background of cells, whereas black-filled histograms represent the uptake fluorescent intensity level of three cIBR-conjugated nanoparticles.

Grahic Jump Location
Fig. 6

Kinetic binding profiles of untargeted-NPs, cIBR-PEG-NPs (tail), cIBR-PEG-NPs (head), and cIBR-NPs (coupling) at 5, 30, and 60 min incubations of Molt-3 cells. Data are presented as mean ± S.D. (n = 3), *** indicates p < 0.0001.

Grahic Jump Location
Fig. 7

HPLC chromatogram of free paclitaxel (a) and paclitaxel-loaded nanoparticles separated on a Hypersil ODS 5 μm column (4 × 250 mm i.d.). The mobile phase was a mixture of acetronitrile and water (60:40 (v/v)) delivered at a flow rate of 1.0 ml/min. Detection: 227 nm.

Grahic Jump Location
Fig. 8

In vitro drug release profile of the cIBR-PTX-NPs (coupling), cIBR-PEG-PTX-NPs (tail), and cIBR-PEG-PTX-NPs (head) in a phosphate buffer (pH 7.4) over 30 days at 37 °C. The error bars indicate the standard deviation of mean for n = 3 independent experiments.

Grahic Jump Location
Fig. 9

Cytotoxicity profiles of blank untargeted-nanoparticles and three blank cIBR-conjugated nanoparticles on the Molt-3 cell lines, measured by the MTT assay. Results are represented in triplicate.

Grahic Jump Location
Fig. 10

Cytotoxicity results from free paclitaxel (PTX), cIBR-PTX-NPs, cIBR-PEG-PTX-NPs (head), and cIBR-PEG-PTX-NPs (tail) to the Molt-3 cell lines. Results are represented in triplicate.

Tables

Errata

Discussions

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging and repositioning the boxes below.

Related Journal Articles
Related eBook Content
Topic Collections

Sorry! You do not have access to this content. For assistance or to subscribe, please contact us:

  • TELEPHONE: 1-800-843-2763 (Toll-free in the USA)
  • EMAIL: asmedigitalcollection@asme.org
Sign In